SCHEDULE 13G/A: Biotechnology Value Fund Group Amends Kura Oncology Stake, Disclosing 4.3% Beneficial Ownership

A group of investment entities led by Biotechnology Value Fund, including Mark N. Lampert, has filed an amendment to their Schedule 13G, disclosing a collective beneficial ownership of 4.3% in Kura Oncology, Inc. as of December 31, 2024.

Summary

• The filing is Amendment No. 4 to Schedule 13G for Kura Oncology, Inc. (CUSIP: 50127T109), detailing beneficial ownership of its Common Stock.
• The reporting group includes Biotechnology Value Fund, L.P. (BVF), Biotechnology Value Fund II, L.P. (BVF2), Biotechnology Value Trading Fund OS LP, and their respective general partners and management entities, with Mark N. Lampert as the ultimate controlling person.
• As of December 31, 2024, the aggregate beneficial ownership by the group (BVF Partners L.P., BVF Inc., and Mark N. Lampert) in Kura Oncology, Inc. common stock totals 3,408,054 shares, representing approximately 4.3% of the outstanding shares.
• This ownership includes 840,585 shares underlying Pre-Funded Warrants, which are exercisable at $0.0001 per share, do not expire, and were not limited by the 9.99% beneficial ownership blocker as of the reporting date.
• Individual beneficial ownership percentages within the group are: BVF at approximately 2.2% (1,751,852 shares), BVF2 at approximately 1.8% (1,410,347 shares), and Trading Fund OS at less than 1% (177,882 shares).
• The percentages are calculated based on 77,763,750 shares outstanding as of November 4, 2024, as reported in the Issuer's Form 10-Q, plus the exercisable Pre-Funded Warrants held by the reporting persons.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, indicating a passive investment intent.

Sentiment

Score: 5

Explanation: The document is a routine beneficial ownership disclosure (Schedule 13G Amendment) and does not contain information that inherently indicates positive or negative sentiment regarding the issuer's financial performance or strategic direction. It merely reports a passive investment stake.

Future Outlook

NA

Industry Context

This filing represents a standard disclosure by a significant institutional investor group specializing in biotechnology, indicating a notable, but passive, investment stake in Kura Oncology, Inc. It provides transparency regarding the ownership structure of a publicly traded biotechnology company.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant passive ownership by an institutional investor group, confirming a notable investment by a specialized fund in the biotechnology sector.

Key Dates

Keywords

Kura Oncology, SEC filing, Schedule 13G, beneficial ownership, institutional investor, Biotechnology Value Fund, Mark N. Lampert, common stock, pre-funded warrants, passive investment, biotechnology